Jump to Content
HOME
BROWSE
SUBJECTS
CLINICAL RESOURCES
DRUG INFORMATION
EDUCATION AND TRAINING
PHARMACY PRACTICE
CAREER DEVELOPMENT
AJHP
DRUG INFORMATION
PROFESSIONAL DEVELOPMENT
Sign in
Sign up
SEARCH
Advanced Search
Help
Sign in
Sign up
HOME
BROWSE
SUBJECTS
CLINICAL RESOURCES
DRUG INFORMATION
EDUCATION AND TRAINING
PHARMACY PRACTICE
CAREER DEVELOPMENT
AJHP
DRUG INFORMATION
PROFESSIONAL DEVELOPMENT
SEARCH
Advanced Search
Help
Search within results
Search within results
Filter
Filter
Refine by Subjects
Clinical Resources
(932)
Drug Information
(2,044)
Refine by Access
All content
Content accessible to me
Refine by Type
Books
(7)
Chapters
(2,037)
Submit
Refine by Date
From
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2008
2002
—
To
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2008
2002
Submit
Print
Save
Email this link
Share Link
Copy this link, or click below to email it to a friend
Email this link
or copy the link directly:
https://publications.ashp.org/collection/DrugInfo?access=all&page=21&pageSize=50&sort=datedescending&t=DrugInfo
The link was not copied. Your current browser may not support copying via this button.
Link copied successfully
Copy link
Share on facebook
Share on linkedin
Share on twitter
Browse
You are looking at
1,001
-
1,050
of
2,044
items for
:
Drug Information
x
Refine by Access: All content
x
Clear All
Items per page:
10
20
50
Sort by:
Title A - Z
Title Z - A
Author A - Z
Author Z - A
Date - Old to Recent
Date - Recent to Old
Page: ...
16
17
18
19
20
21
22
23
24
25
26
...
Restricted access
Fluoxetine Hydrochloride Syrup 1 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Fluoxetine Hydrochloride Syrup 2 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Furosemide Suspension 2 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Furosemide Suspension 9.6 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Gabapentin Suspension 100 mg/mL—Formulation 1
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Gabapentin Suspension 100 mg/mL—Formulation 2
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Gabapentin Suspension 50 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Ganciclovir Intravitreous Solution 20 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Gentamicin Sulfate Ophthalmic Solution 13.6 mg/mL (Fortified)
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Glutamine Suspension 250 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Glycopyrrolate Suspension 0.2 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Glycopyrrolate Suspension 0.5 mg/mL—Formulation 1
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Glycopyrrolate Suspension 0.5 mg/mL—Formulation 2
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Granisetron Hydrochloride Suspension 0.05 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Granisetron Hydrochloride Syrup 0.2 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Haloperidol Suspension 0.5 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Hydralazine Hydrochloride Suspension 4 mg/mL*
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Hydrochlorothiazide Suspension 2 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Hydrocortisone Hemisuccinate Suspension 2 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Hydrocortisone Sodium Phosphate Suspension 2 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Hydrocortisone Suspension 1 mg/mL—Formulation 1
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Hydrocortisone Suspension 1 mg/mL—Formulation 2
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Hydrocortisone Suspension 2 mg/mL*
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Hydroxychloroquine Sulfate Suspension 25 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Hydroxyurea Syrup 100 mg/mL*
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Hypromellose Suspension 10 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Imatinib Syrup 40 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Imipramine Hydrochloride Suspension 5 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Indinavir Liquid 10 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Indomethacin Syrup 2 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Isoniazid Suspension 10 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Isradipine Syrup 1 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Itraconazole Suspension 20 mg/mL—Formulation 1
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Itraconazole Suspension 20 mg/mL—Formulation 2
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Itraconazole Syrup 40 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Ketoconazole Suspension 20 mg/mL—Formulation 1
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Ketoconazole Suspension 20 mg/mL—Formulation 2
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Ketoprofen Suspension 20 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Labetalol Hydrochloride Suspension 40 mg/mL—Formulation 1*
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Labetalol Hydrochloride Suspension 40 mg/mL—Formulation 2
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Labetalol Hydrochloride Syrup 10 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Lamotrigine Suspension 1 mg/mL—Formulation 1
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Lamotrigine Suspension 1 mg/mL—Formulation 2
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Lansoprazole Solution 3 mg/mL*
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Lansoprazole Suspension 3 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Lapatinib Suspension 50 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Lenalidomide Suspension 1.25 mg/mL
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
LET (Lidocaine 4%/Racepinephrine 0.225%/Tetracaine 0.5%) Topical Solution
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Levodopa 5 mg/mL and Carbidopa 1.25 mg/mL Suspension—Formulation 1
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Restricted access
Levodopa 5 mg/mL and Carbidopa 1.25 mg/mL Suspension—Formulation 2
Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes
Chapter
In
Extemporaneous Formulations
Published (Print):
Jan 2022
Items per page:
10
20
50
Sort by:
Title A - Z
Title Z - A
Author A - Z
Author Z - A
Date - Old to Recent
Date - Recent to Old
Page: ...
16
17
18
19
20
21
22
23
24
25
26
...
[3.237.15.145]
3.237.15.145